Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis
Clozapine is the most effective medication for treatment-refractory schizophrenia. However, it has a high burden of adverse events, including common adverse events such as sialorrhea. Sialorrhea can lead to severe physical complications such as aspiration pneumonia, as well as psychological complications including embarrassment and low self-esteem. Compromised adherence and treatment discontinuation can occur due to intolerability. There have been no meta-analyses examining strategies to mitigate clozapine-induced sialorrhea.
We systematically searched Chinese and Western research databases for randomised controlled trials examining agents for clozapine-induced sialorrhea. No limit to language or date were applied to the search. Where sufficient data for individual agents was available, pairwise meta-analyses were conducted. Results were provided as risk ratios and number needed to treat. Sensitivity analysis was conducted by study quality. Adverse events were provided as number needed to harm.
19 studies provided data for use in the meta-analysis. Improvement in clozapine-induced sialorrhea was seen in meta-analyses of propantheline (studies = 6, risk ratio [RR] 2.38, 95% confidence interval [CI] 1.52–3.73; number needed to treat [NNT] 3, 95% CI 1.9–2.7), diphenhydramine (studies = 5, RR 3.09, 95% CI 2.36–4.03; NNT 2, 95% CI 1.5–2.0), chlorpheniramine (studies = 2, RR 2.37, 95% CI 1.59–3.55; NNT 3, 95% CI 1.6–3.5), and benzamide derivatives (odds ratio [OR] 6.93, 95% CI 3.03–15.86). When meta-analyses were limited to high-quality studies, all these results remained significant. Single studies of benzhexol, cyproheptadine, doxepin and Kongyan Tang showed promise. Propantheline increased rates of constipation with a number needed to harm (NNH) of 9 (95% CI 4.2–204.1).
Clozapine-induced sialorrhea is a potentially serious adverse event. Included studies in this meta-analysis were limited by poor study quality. Diphenhydramine, chlorpheniramine and benzamide derivatives appear to have the best supporting evidence and lowest reported adverse events. Caution should be exercised when using propantheline given its increased risk of constipation.
Compliance with Ethical Standards
Dan Siskind is supported in part by an NHMRC ECF APP1111136. The authors have no other funding to disclose.
Conflict of interest
Shih-Yu Chen, Gopi Ravindran, Qichen Zhang, Steve Kisely and Dan Siskind declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
- 1.Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.Google Scholar
- 2.Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2016;174(3):216–29.Google Scholar
- 3.Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–92.Google Scholar
- 4.Land R, Siskind D, Mcardle P, Kisely S, Winckel K, Hollingworth SA. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(4):296–309.Google Scholar
- 5.Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101–9.Google Scholar
- 6.Rohde C, Polcwiartek C, Kragholm K, Ebdrup B, Siskind D, Nielsen J. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatrica Scandinavica. 2018;137(1):47–53.Google Scholar
- 10.Liang C-S, Ho P-S, Shen L-J, Lee W-K, Yang F-W, Chiang K-T. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res. 2010;119(1–3):138–44. https://doi.org/10.1016/j.schres.2010.02.1060.Google Scholar
- 14.Ignjatović Ristić D, Cohen D, Obradović A, Nikić-Đuričić K, Drašković M, Hinić D. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord J Psychiatry. 2018;72(2):124–9. https://doi.org/10.1080/08039488.2017.1400097.Google Scholar
- 16.Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig. 1999;17(2):97–102.Google Scholar
- 19.Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011. http://handbook.cochrane.org.
- 20.Barendregt JJ, Doi SA. MetaXL user guide version 5.3. EpiGear International Pty Ltd; 2016.Google Scholar
- 21.Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21(2):99–103.Google Scholar
- 23.Man W, Colen-de KJ, Schulte P, Cahn W, Haelst I, Doodeman H, et al. The effect of glycopyrrolate on nocturnal sialorrhea in patients using clozapine: a randomized, crossover, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2017. https://doi.org/10.1097/jcp.0000000000000657.Google Scholar
- 24.Xu H, Dong A, Zhang T, Shu W. Diphenhydramine for clozapine -induced salivation at various dosage levels. New Drugs Clin Rem. 1997;16(04):14–6.Google Scholar
- 25.Yang S, Shundi X, Yin Y. A double-blinded placebo-controlled trial on the use of cyproheptadine in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Disord. 1996;08(01):12–3.Google Scholar
- 26.Lin H. A double-blinded placebo-controlled trial on the use of propantheline in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Dis. 1999;25(05):316–7.Google Scholar
- 27.Yang H, Huang S, Feng C, Chen J. A study on the treatments for clozapine-induced sialorrhoea. J Binzhou Med Coll. 1999;22(05):451.Google Scholar
- 28.Gong G, Yuan L, Qin D, Li H, Zhao L, Hu C, et al. A double-blinded placebo-controlled randomized trial on the use of diphenhydramine, propantheline and astemizole in clozapine-induced sialorrhoea. Chin J Psychiatry. 1998;31(03):10.Google Scholar
- 29.Tao J, Yin X, Liu J. A randomized controlled trial on the use of sulpiride in clozapine-induced sialorrhoea. Neurol Disord Ment Health. 2007;07(02):141–3.Google Scholar
- 30.Qin J, Cui C, Ge F. A comparison of treatments for clozapine-induced sialorrahoea. Chin J Clin Psychiatry. 1999;09(04):225–6.Google Scholar
- 31.Fan Z, Zheng C, Li S. A placebo-controlled trial on the use of propantheline in clozapine-induced sialorrhoea. Strait Pharm J. 1996;08(02):33–4.Google Scholar
- 32.Cheng J, Jiang S. A study on the use of benzhexol in clozapine-induced sialorrhoea. J Mod Chin Integr Med. 2005;14(16):2135–6.Google Scholar
- 33.Zhao Z, Chen H, Xie B, Sun S, Wu H, Ma Q, et al. A controlled trial on the use of Zhiyan capsule in clozapine-induced sialorrhoea. Med J Chin Civ Admin. 2000;12(02):34–5.Google Scholar
- 34.Lu X, Xue S, Yang M. The use of diphehydramine in clozapine-induced sialorrhoea. Sichuan J Ment Health. 1998;11(01):38–40.Google Scholar
- 35.Lu L, Liu G, Zhao J, Liu A, Liu S, Liu L, et al. A double-blinded placebo-controlled trial on the use of chlorpheniramine in clozapine-induced sialorrhoea. Chin J Neuropsychiatr Dis. 1994;27(04):252–3.Google Scholar
- 36.Li Z, Song Z, Cheng P, Li C, Xiang X, Shi H. A double-blinded controlled trial on the use of astemizole in clozapine-induced sialorrhoea. Chin J Clin Psychiatry. 1993;03(01):34–5.Google Scholar
- 37.Mao Z, Yang Y, Wang Y, Ma J, Cheng J. A controlled trial on the use of traditional chinese medication Kongyan Decoction in clozapine-induced sialorrhoea. In: The 12th national academic conference on integrated traditional Chinese medicine and western medicine in Psychiatry. Lanzhou, Gansu, China. 2013.Google Scholar
- 38.Qian Q, Gao Z. The use of topical Wu Dan San on acupuncture points inclozapine-induced sialorrhoea. Shanghai Arch Psychiatry. 1996;08(02):103.Google Scholar
- 41.Webber MA, Szwast SJ, Steadman TM, Frazer A, Malloy FW, Lightfoot JD, et al. Guanfacine treatment of clozapine-induced sialorrhea. J Clin Psychopharmacol. 2004;24(6):675–6.Google Scholar
- 43.Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentiallydangerous side effect. J Psychiatry Neurosci. 1999;24(31):250.Google Scholar
- 44.Sharma A, Ramaswamy S, Dahl E, Dewan V. Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea. Ann Pharmacother. 2004;38(9):1538.Google Scholar
- 45.Comley C, Galletly C, Ash D. Use of atropine eye drops for clozapine induced hypersalivation. Aust N Z J Psychiatry. 2000;34(6):1033–4.Google Scholar
- 46.Gaftanyuk O, Trestman R. Scopolamine patch for clozapine-induced sialorrhea. Psychiatr Serv. 2004;55(3):318.Google Scholar
- 47.McKane J, Hall C, Akram G. Hyoscine patches in clozapine-induced hypersalivation. Psychiatr Bull. 2001;25(7):277.Google Scholar
- 49.Duggal H. Glycopyrrolate for clozapine-induced sialorrhea. Prog Neuro Psychopharmacol Biol Psychiatry. 2007;31:1546–7.Google Scholar
- 50.MIMS. MIMS online. Crows Nest, N.S.W: monthly index of medical specialities Australia; 1996.Google Scholar
- 51.Parfitt K, Martindale W. Martindale: the complete drug reference. London: Pharmaceutical Press; 1999.Google Scholar
- 52.Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001;51(2):133–42.Google Scholar
- 53.WHO. Astemizole: voluntary withdrawal: Janssen, USA. WHO Pharmaceuticals Newsletter. 1999.Google Scholar
- 54.Caldara R, Masci E, Cambielli M, Tittobello A, Piepoli V, Barbieri C. Effect of sulpiride isomers on gastric acid and gastrin secretion in healthy man. Eur J Clin Pharmacol. 1983;25(3):319–22.Google Scholar
- 56.Siskind DJ, Lee M, Ravindran A, Zhang Q, Ma E, Motamarri B, Kisely S. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52:751–67.Google Scholar